Vaxart マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Steven Lo

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	3.1yrs
取締役会の平均在任期間	3.3yrs

経営陣の近況

Recent updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

CEO（最高経営責任者

Steven Lo (57 yo)

less than a year

在職期間

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sean Tucker	Senior VP & Chief Scientific Officer	14.8yrs	US$1.14m	0.10% $ 144.2k
James Cummings	Chief Medical Officer	3.3yrs	US$1.17m	0.063% $ 87.8k
Steven Lo	President	less than a year	データなし	データなし
Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	2yrs	データなし	0.041% $ 56.3k
Raymond Stapleton	Chief Technology Officer	2.3yrs	データなし	データなし
Edward Berg	Senior VP & General Counsel	2.8yrs	データなし	0.050% $ 68.9k
Shaily Garg	Senior Vice President of Clinical Development & Project Management	4.8yrs	データなし	データなし
Rajesh Kapoor	Senior Vice President of Quality	3.9yrs	データなし	データなし

3.1yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: VXRTの経営陣は経験豊富であると考えられます ( 3.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Steven Lo	President	less than a year	データなし	データなし
Robert Yedid	Independent Director	5.2yrs	US$92.26k	0.0081% $ 11.3k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	3.3yrs	データなし	データなし
Elaine Heron	Independent Director	2.3yrs	US$89.08k	0.011% $ 15.0k
Michael Finney	Independent Chairman of the Board	6.8yrs	US$109.57k	0.29% $ 408.4k
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	3.3yrs	データなし	データなし
David Wheadon	Independent Director	3.7yrs	US$93.72k	0.0065% $ 9.0k
Robert Belshe	Member of Scientific & Clinical Advisory Board	3.3yrs	データなし	データなし
William Watson	Independent Director	2.3yrs	US$94.76k	0.023% $ 31.8k
Marion Pepper	Member of Scientific & Clinical Advisory Board	3.3yrs	データなし	データなし
Ralph Baric	Member of Scientific & Clinical Advisory Board	3.3yrs	データなし	データなし
Gregory Gray	Member of Scientific & Clinical Advisory Board	3.3yrs	データなし	データなし

3.3yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: VXRTの取締役会は経験豊富であると考えられます ( 3.3年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/24 02:33
終値	2024/12/24 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Vaxart, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。6

アナリスト	機関
Mayank Mamtani	B. Riley Securities, Inc.
Charles Duncan	Cantor Fitzgerald & Co.
Vernon Bernardino	H.C. Wainwright & Co.

Vaxart マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

High number of new and inexperienced directors

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Recent updates

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

New major risk - Financial position

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Consensus revenue estimates increase by 113%, EPS downgraded

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Consensus revenue estimates increase by 865%

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Price target increased by 11% to US$5.25

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Now 27% overvalued after recent price rise

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Consensus revenue estimates increase by 57%

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

New major risk - Share price stability

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

Consensus revenue estimates decrease by 60%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Price target decreased to US$7.75

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021)

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Ray Stapleton joins Vaxart as CTO

Vaxart, Inc. Announces Board Changes

Consensus revenue estimates fall by 12%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Price target decreased to US$9.75

Vaxart shareholders approve proposal to increase number of shares

Vaxart continues to lobby shareholders to vote to increase number of shares

Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Vaxart: A Unique Vaccine Concern

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

マネジメント基準チェック /24